XML 51 R40.htm IDEA: XBRL DOCUMENT
v3.25.1

Acquisitions and Licensing Arrangements - Narrative (Details) - USD ($) $ in Millions |  | 1 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended
--- | --- | --- | --- | --- | ---
Oct. 28, 2024 | Mar. 31, 2025 | Feb. 28, 2025 | Jan. 31, 2025 | Sep. 30, 2025 | Mar. 31, 2025 | Mar. 31, 2024 | Jun. 30, 2026 | Jun. 30, 2026
Asset Acquisition [Line Items] |  |  |  |  |  |  |  |  |
Acquired in-process research and development and milestones |  |  |  |  |  | $ 10 | $ 0 |  |
Suzhou Centergene Pharmaceuticals | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement |  |  |  |  |  |  |  |  |
Asset Acquisition [Line Items] |  |  |  |  |  |  |  |  |
Acquired in-process research and development and milestones |  |  |  |  |  | 6 |  |  |
Shanghai Henlius Biotech, Inc. | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement |  |  |  |  |  |  |  |  |
Asset Acquisition [Line Items] |  |  |  |  |  |  |  |  |
Acquired in-process research and development and milestones |  |  | $ 10 |  |  |  |  |  |
Product Rights | Lilly |  |  |  |  |  |  |  |  |
Asset Acquisition [Line Items] |  |  |  |  |  |  |  |  |
Payment for regulatory milestones |  |  |  | $ 20 |  |  |  |  |
Noncurrent liability |  | $ 240 |  |  |  | $ 240 |  |  |
Biogen Inc. |  |  |  |  |  |  |  |  |
Asset Acquisition [Line Items] |  |  |  |  |  |  |  |  |
Upfront payments |  | 51 |  |  |  |  |  |  |
Currently marketed products - products and product right |  | $ 51 |  |  |  |  |  |  |
Amortize the asset useful life (in years) |  | 10 years |  |  |  | 10 years |  |  |
Biogen Inc. | Achievement Of Commercial Milestones, Tiered Royalties On Net Sales, And Assumption Of Liabilities |  |  |  |  |  |  |  |  |
Asset Acquisition [Line Items] |  |  |  |  |  |  |  |  |
Milestone payment |  | $ 45 |  |  |  | $ 45 |  |  |
Dermavant Sciences Ltd |  |  |  |  |  |  |  |  |
Asset Acquisition [Line Items] |  |  |  |  |  |  |  |  |
Upfront payments | $ 175 |  |  |  |  |  |  |  |
Milestone obligations | 1,025 |  |  |  |  |  |  |  |
Aggregate purchase price consideration | 581 |  |  |  |  |  |  |  |
Dermavant Sciences Ltd | Licensing Agreements |  |  |  |  |  |  |  |  |
Asset Acquisition [Line Items] |  |  |  |  |  |  |  |  |
Payment for regulatory milestones |  |  |  |  |  | 35 |  |  |
Dermavant Sciences Ltd | Milestone Payment Upon Regulatory Approval |  |  |  |  |  |  |  |  |
Asset Acquisition [Line Items] |  |  |  |  |  |  |  |  |
Milestone payment | 75 |  |  |  |  |  |  |  |
Payment for regulatory milestones |  |  |  |  |  | $ 75 |  |  |
Dermavant Sciences Ltd | Achievement Of Commercial Milestones, Tiered Royalties On Net Sales, And Assumption Of Liabilities |  |  |  |  |  |  |  |  |
Asset Acquisition [Line Items] |  |  |  |  |  |  |  |  |
Milestone payment | 950 |  |  |  |  |  |  |  |
Dermavant Sciences Ltd | Cash Payable Upon Regulatory Approval |  |  |  |  |  |  |  |  |
Asset Acquisition [Line Items] |  |  |  |  |  |  |  |  |
Milestone obligations | 75 |  |  |  |  |  |  |  |
Dermavant Sciences Ltd | Cash Payable Achievements Of Certain Commercial Milestones |  |  |  |  |  |  |  |  |
Asset Acquisition [Line Items] |  |  |  |  |  |  |  |  |
Milestone obligations | $ 950 |  |  |  |  |  |  |  |
Oss Biotech Site | Forecast |  |  |  |  |  |  |  |  |
Asset Acquisition [Line Items] |  |  |  |  |  |  |  |  |
Aggregate purchase price consideration |  |  |  |  | $ 15 |  |  | $ 10 | $ 25

X
- Definition Business Combination, Upfront Payments + References No definition available. + Details
Name: | ogn_BusinessCombinationUpfrontPayments
Namespace Prefix: | ogn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 15 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3 + Details
Name: | us-gaap_AssetAcquisitionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 30 -Paragraph 8 -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479637/805-30-30-8 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 30 -Paragraph 7 -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479637/805-30-30-7 + Details
Name: | us-gaap_BusinessCombinationConsiderationTransferred1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of liability recognized arising from contingent consideration in a business combination. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetUsefulLife
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1 + Details
Name: | us-gaap_FinitelivedIntangibleAssetsAcquired1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (f) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details
Name: | us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details
Name: | us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=ogn_SuzhouCentergenePharmaceuticalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=ogn_ShanghaiHenliusBiotechIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractualRightsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=ogn_LillyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=ogn_BiogenInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=ogn_AchievementOfCommercialMilestonesTieredRoyaltiesOnNetSalesAndAssumptionOfLiabilitiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=ogn_DermavantSciencesLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=ogn_MilestonePaymentUponRegulatoryApprovalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=ogn_CashPayableUponRegulatoryApprovalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=ogn_CashPayableAchievementsOfCertainCommercialMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=ogn_OssBiotechSiteMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=srt_ScenarioForecastMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |